Search
01/06/2022
Socioeconomic inequalities and COVID-19 in Spain. SESPAS Report 2022
Bacigalupe, A, Martin, U, Franco, M, Borrell, C. Socioeconomic inequalities and COVID-19 in Spain. SESPAS Report 2022. Gaceta Sanitaria. 2022; 36DOI:10.1016/j.gaceta.2022.01.011. PMID:35781142. IF:1.900(Q3/8D).
01/06/2022
Lyophilized amniotic membrane graft for primary pterygium surgery: preliminary results
Sabater-Cruz, N, Martinez-Conesa, E, Vilarrodona, A, Casaroli-Marano, RP. Lyophilized amniotic membrane graft for primary pterygium surgery: preliminary results. CELL AND TISSUE BANKING. 2022; 23(2)DOI:10.1007/s10561-021-09955-3. PMID:34628551. IF:1.500(Q4/9D).
01/06/2022
Prognosis of acute heart failure based on clinical data of congestion
Espinosa B., Llorens P., Gil V., Rossello X., Jacob J., Herrero P., Martín-Sánchez F.J., Alquézar-Arbé A., Masip J., Miró Ò.. Prognosis of acute heart failure based on clinical data of congestion. REVISTA CLINICA ESPANOLA. 2022; 222(6)DOI:10.1016/j.rce.2021.07.003. PMID:34756646. IF:2.900(Q2/5D).
01/06/2022
Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials
Chabra, S, Gill, BJ, Gallo, G, Zhu, DT, Pitou, C, Payne, CD, Accioly, A, Puig, L. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. ADVANCES IN THERAPY. 2022; 39(6)DOI:10.1007/s12325-022-02126-0. PMID:35449322. IF:3.800(Q2/4D).
01/06/2022
A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence
Medina-Catalan, D, Riera, P, Pages-Puigdemont, N, Masip, M, Lopez-Ferrer, A, Vilarrasa, E, Puig, L. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy. 2022; 44(3)DOI:10.1007/s11096-022-01400-z. PMID:35380392. IF:2.400(Q3/8D).
01/06/2022
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
de Bruin-Weller, MS, Serra-Baldrich, E, Barbarot, S, Grond, S, Schuster, C, Petto, H, Capron, JP, Raibouaa, A, Werfel, T. Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. Dermatology and Therapy. 2022; 12(6)DOI:10.1007/s13555-022-00734-w. PMID:35543919. IF:3.400(Q2/3D).
01/06/2022
[Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2-Management of Special Populations, Patients With Comorbid Conditions, and Risk
Carrascosa, JM, Puig, L, Romero, IB, Salgado-Boquete, L, del Alcazar, E, Lencina, JJA, Moreno, D, de la Cueva, P. [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2-Management of Special Populations, Patients With Comorbid Conditions, and Risk. Actas Dermo-Sifiliograficas. 2022; 113(6)DOI:10.1016/j.ad.2022.01.024. PMID:35748004. IF:(Q/D).
01/06/2022
Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients
Fuchs, TL, Maclean, F, Turchini, J, Vargas, AC, Bhattarai, S, Agaimy, A, Hartmann, A, Kao, CS, Ellis, C, Bonert, M, Leroy, X, Kunju, LP, Schwartz, L, Matsika, A, Williamson, SR, Rao, P, Divatia, M, Guarch, R, Algaba, F, Balancin, ML, Zhou, M, Samaratunga, H, da Cunha, IW, Brimo, F, Ryan, A, Clouston, D, Aron, M, O'Donnell, M, Chan, E, Hirsch, MS, Moch, H, Pang, CY, Wah, C, Yin, WH, Perry-Keene, J, Yilmaz, A, Chou, A, Clarkson, A, van der Westhuizen, G, Morrison, E, Zwi, J, Hes, O, Trpkov, K, Gill, AJ. Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. MODERN PATHOLOGY. 2022; 35(6)DOI:10.1038/s41379-021-00998-1. PMID:34949766. IF:7.500(Q1/1D).